MSD could not challenge Gilead’s rights to sofosbuvir in court
The American pharmaceutical company Merck (outside the US and Canada - MSD) was unable to appeal against patents of Gilead for the drug for the treatment of hepatitis C sofosbuvir. The US Supreme Court rejected the appeal of an organization demanding compensation for violating its rights in the amount of $ 200 million.
It was this amount in March 2016 that the Californian jury ordered to pay MSD. Later, however, this decision was changed because it became known that the claimant company used Pharmasset company acquired Gilead in 2011 when registering patents.
At the beginning of this week, a final decision was made on this case - the Supreme Court rejected the claims of MSD against Gilead.
It is important to note that on the same day, January 7, the court also rejected the appeal of Gilead in the case of accusing the company of using low-quality raw materials in the production of expensive drugs for the treatment of HIV infection Emtriva, Truvada and Atripla.
Recall the criminal case against the world's largest manufacturer of medicines for the treatment of HIV infection and hepatitis C was launched in 2015 in connection with the testimony of its former employees about the supply of cheap substances from China under the guise of registered South Korean.
